The Next-Generation Antibody Therapeutics Global Market Report 2023, provides comprehensive information on the next-generation antibody therapeutics market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Next-Generation Antibody Therapeutics Market’s Growth:
As per The Business Research Company’s Next-Generation Antibody Therapeutics Global Market Report 2023, the global next-generation antibody therapeutics market is expected to grow from $5.44 billion in 2022 to $6.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The next-generation antibody therapeutics market is expected to reach $9.43 billion in 2027 at a CAGR of 11.3%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12678&type=smp
Technological advancements are a key trend gaining popularity in the next-generation antibody therapeutics market. Major companies operating in the next-generation antibody therapeutics market are concentrating on creating technologically advanced products to strengthen their position in the market. For instance, in October 2021, Merck KGaA, a Germany-based science and technology company, launched the new technology ChetoSensar. By addressing solubility issues, ChetoSensar offers renewed hope for antibody-drug conjugates. It has improved the efficacy of its antibody-drug conjugates and high-potency active pharmaceutical ingredient (HPAPI). By enhancing the solubility of antibody-drug conjugates, the novel ChetoSensar technology expands the potential for developing next-generation antibody-drug conjugate therapeutics.
The next-generation antibody therapeutics market is segmented:
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
North America was the largest region in the next-generation antibody therapeutics market in 2022.
The table of contents in TBRC’s next-generation antibody therapeutics market report includes:
- Executive Summary
- Next-Generation Antibody Therapeutics Market Characteristics
- Next-Generation Antibody Therapeutics Market Trends And Strategies
- Next-Generation Antibody Therapeutics Market – Macro Economic Scenario
- Global Next-Generation Antibody Therapeutics Market Size and Growth
.
.
.
- Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking
- Global Next-Generation Antibody Therapeutics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market
- Next-Generation Antibody Therapeutics Market Future Outlook and Potential Analysis
- Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
